Actively Recruiting

Age: 18Years +
All Genders
ID06822634

Advances in Imaging to Assess Response in Rectal Cancer (AIR-REC)

Led by NHS Greater Glasgow and Clyde · Updated on 2025-02-12

20

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the feasibility of using serial MRI images for advanced radiotherapy planning in patients with rectal cancer. This observational study focuses on locally advanced rectal adenocarcinoma, aiming to determine whether repeated MRI scans can improve tumor localization and response assessment during radiotherapy treatment. Rectal cancer is a common type of bowel cancer, and radiotherapy plays a key role in its management, but accurate imaging for treatment planning remains challenging. The study includes patients scheduled for standard neoadjuvant radiotherapy prior to surgery. Radiotherapy regimens typically involve either long course chemoradiotherapy or short course radiotherapy, both widely used internationally. MRI is used to provide better soft tissue visualization compared to CT scans, potentially enabling more precise targeting of the tumor volume during radiotherapy. This study will observe patients over 18 months to collect MRI images and assess changes in tumor volume and imaging parameters. Participants will undergo serial MRI scans and routine radiotherapy treatment as planned by their care team. Researchers will collect data on radiotherapy target volumes, image parameters like apparent diffusion coefficient, and assess inter-observer agreement in target delineation. Quality of life will also be measured using validated questionnaires over 18 months. The primary goal is to determine the practicality of acquiring these MRI images to improve radiotherapy planning for rectal cancer.

CONDITIONS

Brief Title

Advances in Imaging to Assess Response in Rectal Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed rectal adenocarcinoma.
  • T stage 3b or above and/or high risk factors such as EMVI or nodal disease.
  • Able to give written informed consent.
  • Male or non-pregnant female 18 years of age or older.
  • Scheduled to undergo radical radiotherapy.
  • Willing and able to comply with the study protocol for its duration.
Not Eligible

You will not qualify if you...

  • Contraindications to MRI, including claustrophobia, excessive body weight, MRI unsafe implants, ferrous metal in the body, or insufficient information on prior surgeries.
  • MRI conditional implants where conditions cannot be met (e.g., pacemakers).
  • Previous radiotherapy to the pelvis.
  • Inflammatory bowel disease.
  • Severe or uncontrolled systemic disease or any significant disorder making participation undesirable.
  • History of physical or psychiatric disorder preventing consent or compliance.
  • Patients with de-functioning stoma.
  • Major surgery within 28 days prior to trial entry.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Monitoring

Duration - Up to 18 months

Participants scheduled for standard radiotherapy prior to surgery undergo serial MRI imaging to assess tumour response and radiotherapy planning.

Multiple MRI scans during radiotherapy and follow-up

Trial Site Locations

Total: 1 location

1

Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom, G120YN

Actively Recruiting

Loading map...

Research Team

M

Ms Lynsey Devlin

M

Ms Aileen Duffton, PhD Cancer Sciences

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase 1, Open-label, Dose-escalation and Cohort Expansion ...

Solid Tumours

Actively Recruiting

10 locations

Study of ABT-301 With Tislelizumab and Bevacizumab in pMMR/N...

Colorectal Cancer (Diagnosis)

Actively Recruiting

15 locations

A Phase II Study Investigating Fruquintinib Plus FOLFIRI as ...

Colon Cancer

Actively Recruiting

14 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here